Review on Approved and Inprogress Covid-19 Vaccines Publisher



Farnudianhabibi A^{1, 2} ; Mirjani M^{1, 2} ; Montazeri V³ ; Aliebrahimi S⁴ ; Katouzian I⁵ ; Abdolhosseini S⁶ ; Rahmani A^{1, 2} ; Keyvani H⁷ ; Ostad SN⁸ ; Radmalekshahi M^{1, 2} Show Affiliations
Source: Iranian Journal of Pharmaceutical Research Published:2022

Abstract

The last generation of Coronavirus named COVID-19 is responsible for the recent worldwide outbreak. Concerning the widespread and quick predominance, there is a critical requirement for designing appropriate vaccines to surmount this grave problem. Correspondingly, in this revision, COVID-19 vaccines (which are being developed until March 29th, 2021) are classified into specific and non-specific categories. Specific vaccines comprise genetic-based vaccines (mRNA, DNA), vector-based, protein/recombinant protein vaccines, inactivated viruses, live-attenuated vaccines, and novel strategies including microneedle arrays (MNAs), and nanoparticles vaccines. Moreover, specific vaccines such as BCG, MRR, and a few other vaccines are considered Non-specific. What is more, according to the significance of Bioinformatic sciences in the cutting-edge vaccine design and rapid outbreak of COVID-19, herein, Bioinformatic principles including reverse vaccinology, epitopes prediction/selection and, their further applications in the design of vaccines are discussed. Last but not least, safety, challenges, advantages, and future prospects of COVID-19 vaccines are highlighted. © 2022, Author(s).